Anika Therapeutics, Inc. (ANIK) vs Greenwich LifeSciences, Inc. (GLSI)
A side-by-side comparison of Anika Therapeutics, Inc. and Greenwich LifeSciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANIK
Anika Therapeutics, Inc.
$19.21HealthcareDelayed quote: Oct 6, 2026, 10:45 AM EDT
GLSI
Greenwich LifeSciences, Inc.
$16.62HealthcareDelayed quote: Oct 6, 2026, 10:45 AM EDT
Total return — ANIK vs GLSI
growth of $100 · dividends reinvested · last 6yANIK -40.6% (-8.3%/yr)GLSI +238.2% (+22.5%/yr)GLSI compounded faster over this window
Log scale — wide-divergence pair
ANIK GLSI
ANIK vs GLSI: by the numbers
- •ANIK is the larger company ($257M vs $244M market cap).
- •Both run net losses; GLSI's is the smaller (0.00% vs -3.14% net margin).
Metrics side by side
Valuation
| Metric | ANIK | GLSI |
|---|---|---|
| Forward P/E | 18.30 | N/A |
| P/S ratio | 2.13 | N/A |
| P/B ratio | 1.87 | 78.27 |
| EV / EBITDA | 475.42 | N/A |
| FCF yield | 0.22% | N/A |
Profitability
| Metric | ANIK | GLSI |
|---|---|---|
| Gross margin | 62.16% | 0.00% |
| Operating margin | -4.24% | 0.00% |
| Net margin | -3.14% | 0.00% |
| ROE | -2.76% | -695.56% |
| ROIC | -3.17% | -701.55% |
Growth (annualized)
| Metric | ANIK | GLSI |
|---|---|---|
| Revenue CAGR (5Y) | -2.48% | N/A |
| FCF CAGR (5Y) | -39.38% | N/A |
| Total return CAGR (5Y) | -13.40% | -14.84% |
Frequently asked
- How have ANIK and GLSI total returns compared?
- Over the past 5 years, ANIK delivered -13.40% and GLSI delivered -14.84% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.